Capital Guardian Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capital Guardian Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-470	Closed	-$79K	–	365
2018 Q3	$79K	Buy	+470	New	+$80.8K	﹤0.01%	293
2016 Q2	–	Sell	-39	Closed	-$5K	–	737
2016 Q1	$5K	Buy	+39	New	+$4.86K	﹤0.01%	683

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Guardian Trust's JAZZ Position: Q4 2018 in Review

Capital Guardian Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 470 shares — an estimated $79K sold.

Capital Guardian Trust first reported a position in JAZZ in Q1 2016 and held it in 2 quarters. The position peaked at $79K in Q3 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

Capital Guardian Trust reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Capital Guardian Trust sold 470 Jazz Pharmaceuticals shares in Q4 2018, an estimated $79K.
Capital Guardian Trust first reported a position in Jazz Pharmaceuticals in Q1 2016 and held it in 2 quarters.
Capital Guardian Trust's Jazz Pharmaceuticals position peaked at $79K in Q3 2018.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Capital Guardian Trust's 13F filing for Q4 2018, filed 14 Feb 2019.